Nigerian Journal of Clinical Practice, vol.24, no.10, pp.1545-1550, 2021 (SCI-Expanded)
© 2021 Wolters Kluwer Medknow Publications. All rights reserved.Aims: Gelatin-thrombin matrix (GTM) is a hemostatic agent with applications in maxillofacial surgery consisting of human-derived thrombin and bovine-derived gelatin matrix. The aim of this study was to evaluate the efficacy of GTM alone or with freeze-dried bone allograft (FDBA) in improving early bone healing. Materials and Methods: Forty-six adult male Sprague-Dawley rats were used. All animals were randomly assigned to a control group (n = 4) and three study groups (n = 14). Each group was divided into two subgroups for histomorphometric and histological analyses at weeks 1 and 4. The new bone formation, inflammation, fibrosis, necrosis, foreign body reaction, and bone healing scores were evaluated based on the histopathological findings. Multiple comparisons were performed using the Kruskal-Wallis test. Variables that were not normally distributed were evaluated using the Mann-Whitney U test. Results: At 1 week, the GTM + FDBA group showed less bone formation (mean ± SD: 0.08 ± 0.03 mm 2), compared with the study and control groups (FDBA: 0.15 ± 0.06 mm 2; GTM: 0.13 ± 0.06 mm 2). At 4 weeks, the GTM group (0.48 ± 0.1 mm 2) showed more bone formation than the GTM + FDBA group (0.33 ± 0.17 mm 2). Foreign body reactions were observed at weeks 1 and 4 in all GTM-containing groups. Conclusions: Within the limitations of this study, GTM group did not show a significant difference in bone formation compared with the control group. GTM did not inhibit bone healing at 1 and 4 weeks, and no significant difference was observed compared with the control groups. GTM was more effective for bone healing when administered without FDBA. GTM is considered safe when bone hemorrhage is encountered.